Management of Low Hemoglobin in Patients on Anticoagulants

Assessment and Management of Bleeding

For patients on anticoagulants with low hemoglobin, the American College of Cardiology recommends immediately assessing bleeding severity and implementing appropriate management strategies based on the presence of critical site bleeding, hemodynamic instability, or significant hemoglobin drop (≥2 g/dL) or need for blood transfusion (≥2 units) 1, 2
Determine if the patient meets criteria for major bleeding by checking for at least one of the following factors: bleeding at a critical site, hemodynamic instability, or clinically overt bleeding with hemoglobin decrease ≥2 g/dL or administration of ≥2 units RBCs 2, 3
Laboratory evaluation should include complete blood count to assess hemoglobin level and hematocrit, coagulation studies, and assessment for comorbidities that could contribute to bleeding 1, 2, 3

If the patient meets criteria for major bleeding, stop oral anticoagulation and any antiplatelet agents immediately, and consider specific reversal agents based on the anticoagulant type 1, 4
For patients on vitamin K antagonists, administer 5-10 mg IV vitamin K and consider prothrombin complex concentrates or specific reversal agents 1, 4
For patients on DOACs, consider specific reversal agents, such as idarucizumab for dabigatran or andexanet alfa for apixaban or rivaroxaban 1, 4
Provide local therapy and manual compression when applicable, and implement supportive care and volume resuscitation 1

Once bleeding is controlled and the patient is stable, assess if there is a clinical indication for continued anticoagulation, and consider factors such as critical site bleed, high risk of rebleeding, and source of bleeding identification 4
For patients with high thrombotic risk, restart anticoagulation as soon as hemostasis is achieved, while for patients with lower thrombotic risk, consider delaying restart of anticoagulation until the risk of rebleeding is minimized 4, 6